Immunomodulation of proteoglycan-induced progressive polyarthritis by lefluflomide

Immunopharmacology

Volumn 23, Issue 2, 1992, Pages 105-116

  Giant, Tibor T ^a   Mikecz, Katalin ^a   Bartlett, Robert R ^b   Deák, Ferenc ^c   Thonar, Eugene J M A ^a   Williams, James M ^a   Mattar, Thomas ^b   Kuettner, Klaus E ^a   Schleyerbach, Rudolf ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b SANOFI   (France)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Arthritis; Autoantibody; Autoimmune; HWA 486; Immunomodulation; Inflammation; Leflunomide; Proteoglycan

Indexed keywords

ANTIBODY; IMMUNOMODULATING AGENT; LEFLUNOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANIMAL; ARTHRITIS; AUTOANTIBODIES; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MICE; MICE, INBRED BALB C; PROTEOGLYCANS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026589680     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/0162-3109(92)90034-A     Document Type: Article

References (30)

1. immunophannacological profile of HWA 486, a novel isoxazol derivative. II. In vivo imniunomodulating effects differ from those of cyclophosphamide, prednisolone, or cyclosporin A
2. (HWA 486), a novel immuno-modulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection
3. (HWA 486): a novel immunorestoring drug
4. Development of autoimmunity in MRL/lpr mice and the effect of drugs on this murine disease
5. Immunophannacological profile of a novel isoxazol derivative. HWA 486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis of the rat
6. Cartilage proteoglycan-induced arthritis in BALB/c mice: antibodies recognize human and mouse cartilage proteoglycan and can cause riepletion of cartilage proteoglycan with little or no synovitis
7. Binding of G-CSF, GM-CSF, tumor necrosis factor-α and γ-interferon to cell surface receptors on human myeloid leukemia cells triggers rapid tyrosine and serine phosphorylation of a 75-kD protein
8. IL-1 induces rapid phosphorylation of the IL-1 receptor
9. Proteoglycan-specific autoreactive antibodies and T-lymphocytes in experimental arthritis and human rheumatoid joint diseases
10. Proteoglycan-induced arthritis in BALB/c mice: clinical features and histopathology
11. Antiproteoglycan antibodies in experimental spondylitis
12. Monoclonal antibodies to different protein-related epitopes of human articular cartilage proteoglycans
13. 2 activation
14. Drug action on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis
15. Aggregation of cartilage proteoglycans. I. The role of hyaluronic acid
16. Transp Proc
17. Cartilage proteoglycans as potential autoantigens in humans and in experimental animals
18. Proteoglycan-induced arthritis and spondylitis adoptively transferred to naive (non-immunized) BALB/c mice
19. Immunity to cartilage proteoglycans in BALB/c mice with progressive polyarthritis and ankylosing spondylitis induced by injection of human cartilage proteoglyean
20. Interleukin 2-induced tyrosine phosphorylation. Interleukin2 receptor β is tyrosine phosphorylated
21. Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis
22. Interleukin-3-induced activation of protein kinases in the mast cell/megakaryocyte R6-Xe.4 line
23. Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice
24. The use of the murine chronic graft Vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery
25. Studies of sialic acid-containing mucins in bovine submaxillary and rat sublingual glands
26. The haematoxylins
27. Leflunomide (HWA 486) inhibits experimental autoimmune tubulointestinal nephritis in rats
28. Epidermal growth factor and related molecules